Business Bites: K2M files for $100m IPO; STAAR's toric lens gets panel thumbs-up
This article was originally published in Clinica
Executive Summary
Spinal device specialist K2M is taking a punt on the public markets, hoping to raise $100m in an initial public offering. The firm did not give details about how many shares it plans to sell or at what price. If successful, Leesburg, Virginia-based K2M will list on Nasdaq under the ticker symbol KTWO. Founded in 2004, the company sells 57 different product lines related to the repair of the spine and booked revenues of $157.6m in 2013, up 17% year-on-year. The firm’s flagship MESA technology accounted for 35% of these sales. K2M believes its products are less invasive and allow simpler surgery than rival spinal devices, it said in a filing with the US Securities and Exchange Commission. It appears to be nearing break-even point, narrowing its net loss to $8.3m last year, from $13.0m in 2012.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.